


Peptide Manufacturing: Chemical Synthesis vs Recombinant Expression with SUMO-Fusions



LifeSensors Inc.
271 Great Valley Parkway
Malvern PA 19355


610-644-8845
BD@Lifesensors.com
www.Lifesensors.com

SUMO Polypeptide Factories

- LifeSensors is the developer of SUMO protein expression platform
- Chemical synthesis of poly-peptides beyond 30 amino acids is costly and suffers from poor quality, especially for therapeutic peptides
- Recombinantly expressed peptides are rapidly degraded in E.coli
- SUMO system improves quality of polypeptides, increases the yield and decreases cost

Factors that Enhance SUMO Poly-peptide Manufacturing

- Nature designed SUMO to act as a chaperone for proteins
- SUMO, or Small Ubiquitin-like MOdifier, is a member of the ubiquitin family
- Flexible N-terminal region followed by a compact ball-shaped ubiquitin-like fold
- SUMO improves solubility due to hydrophilic outer surface and hydrophobic core



SUMO Platform for Polypeptide Manufacturing

PROBLEMS

Unstable polypeptide,
low expression

Insoluble polypeptide

Miss-folded polypeptide

High cost of goods



SOLUTIONS


SUMO chaperoning,
stabilizes polypeptides

SUMO derived solubility


SUMO-driven folding

High yield, saves cost


SUMO Platform For Polypeptides



SUMO Polypeptide Expression and Purification Process




SUMOpro[®] fusion enhances expression and solubility in *E. coli*



Conditions: UN – Uninduced, IN – Induced, S – Soluble Fraction, IB – Inclusion Bodies

Marblestone et. al, Protein Sci. 2006 Jan;15(1):182-9

Dramatic increase in yield, improved quality and decrease cost of SUMO-mediated polypeptide manufacturing



Polypeptide Manufacturing: Chemical vs Recombinant

Chemical Synthesis

- Chemical synthesis is error prone and costly beyond 30 amino acid in length
- Polypeptide yield decreases with increasing length and quality suffers
- Not all the chemically synthesized peptides fold correctly

SUMO Manufacturing

- Recombinantly expressed peptides are **rapidly degraded** in E.coli. Fusion with **SUMO provides remarkable stability** thus increasing the yield.
- Desired N-terminal of peptides are generated that is **not possible with traditional expression systems**
- Correct folding in cells provides biologically/structurally active peptides, low cost

Therapeutic peptides in the Clinic

Therapeutic peptide	Production method	Company	Indication
Insulin	Recombinant (E.coli)	Lilly , Novo Nordisk, Sanofi	Diabetes
Growth hormone	Recombinant (E.coli, yeast)	Genentech , Pfizer , Sandoz	Growth disorders
GnRH analogues	Recombinant (E.coli)	AbbVie	Prostate cancer, endometriosis, precocious puberty
Abaloparatid/Etelcalcetide (PTHrP)	Recombinant (E.coli)	Radius Health	Osteoporosis
Teriparatide (PTH)	Recombinant (E.coli)	Eli Lilly	Osteoporosis
Lixisenatide (GLP-1 analog)	Recombinant (E.coli)/Chemical synthesis	Sanofi, Amylin	Type 2 diabetes
Enfuvirtide	Chemical synthesis	Roche	HIV-1 infection
LL-37	Chemical synthesis	R&D , Sigma	Under development, Antimicrobial
TRAIL/Apo2L	Recombinant (E.coli)	Sigma	Cytotoxic, for use in cancer

Examples of SUMO-enhanced production of therapeutic peptides

	Peptide Name	Host	Yield (mg/L)
Antimicrobial Peptides	ABP-CM4 ¹	E.coli	24 mg/L
	Bacteriophage-encoded endolysin, LysP11 ²	Nicotiana benthamiana leaves	8 mg/kg
	Abaecin ³	E.coli	-
	Hepcidin25 ⁵	E.coli	3.9 mg/L
	Cationic antimicrobial host defense peptides (HDPs) ⁶	E.coli in fermentation flask	16-80 mg/L
	AP-64, a human anti-microbial peptide ⁷	E.coli	-
	Cytotoxic Peptides	Edema Toxin from Bacillus anthracis ⁸	E.coli
Recombinant cytotoxin II (rCTII) from Naja naja Oxiana venom ⁹		E.coli	-
Phospholipase D from the spider Loxosceles gaucho ¹⁰		E.coli	24 mg/L
Scolopin 1 from centipede venom ^{11,12}		E.coli	16 mg/L
Anti-thrombotic Peptides		Tsetse fly salivary protein ¹³	E.coli
	Ixodes ricinus Salivary Serpin Iripin-8 ¹⁴	E.coli	23 mg/L

1. [Li, J.F. et al, Appl Microbiol Biotechnol, 2009](#)

2. [Islam, M.R., Plant Cell Rep, 2019](#)

3. [Kim DS et al, BMC Biotechnol. 2019](#)

4. [Mo Q et al, Lett Appl Microbiol. 2018](#)

5. [Sadr V et al, Gene. 2017](#)

6. [Bommarius B et al, Peptides. 2010](#)

7. [Zhong K et al, Biomolecules. 2021](#)

8. [Yang NJ et al, Front Immunol. 2021](#)

9. [Derakhshani A et al, Int J Biol Macromol. 2020](#)

10. [Shimokawa-Falcão LH, Toxins \(Basel\). 2017](#)

11. [Chu Y et al, Toxins \(Basel\). 2020](#)

12. [Hou H et al, Protein Expr Purif. 2013](#)

13. [Caljon G et al, PLoS One. 2010](#)


14. [Kotál J et al, Int J Mol Sci. 2021](#)

Cationic antibacterial peptide ABP-CM4

Table 2 Comparison of the SUMO fusion partner with Trx or Intein fusion partners

Fusion protein	Time cost (days)	Cleavage efficiency (%)	Yield (mg/l)
Trx-CM4	4-5	<70	1.2-12
Intein-CM4	3	80	4.2
SUMO-CM4	2	>90	24

Li, J.F. et al, Appl Microbiol Biotechnol, 2009



SUMO system is superior to chemical synthesis

- **SUMO dramatically enhances the yield of polypeptides, preserving biological activity and maintaining the QC.**
- **SUMO generates desired N-terminus of the peptide.**
- **SUMO system reduces the cost of peptide synthesis.**

Thank You

We are your partner in Manufacturing Needs

Contact Us!

Research & Product Inquiries	R&D	info@lifesensors.com	610-644-8845 (ext 339)
Custom Service & Assays	BD	bd@lifesensors.com	610-644-8845 (ext 310)